Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leslie Amass

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Plos One|January 19, 2024
Phenotypic characteristics of F64L, I68L, I107V, and S77Y ATTRv genotypes from the Transthyretin Amyloidosis Outcomes Survey (THAOS)Luca Gentile, Igor Diemberger, Violaine Plante-Bordeneuve, et al.
The American Journal on Addictions|June 19, 2004
Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experienceLeslie Amass, Walter Ling, Thomas E Freese, et al.
Drug and Alcohol Dependence|September 23, 2008
Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependenceDouglas M Ziedonis, Leslie Amass, Marc Steinberg, et al.
Orphanet Journal of Rare Diseases|November 10, 2023
A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS)Luca Gentile, Teresa Coelho, Angela Dispenzieri, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Plos One|January 19, 2024
Phenotypic characteristics of F64L, I68L, I107V, and S77Y ATTRv genotypes from the Transthyretin Amyloidosis Outcomes Survey (THAOS)Luca Gentile, Igor Diemberger, Violaine Plante-Bordeneuve, et al.
The American Journal on Addictions|June 19, 2004
Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experienceLeslie Amass, Walter Ling, Thomas E Freese, et al.
Drug and Alcohol Dependence|September 23, 2008
Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependenceDouglas M Ziedonis, Leslie Amass, Marc Steinberg, et al.
Orphanet Journal of Rare Diseases|November 10, 2023
A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS)Luca Gentile, Teresa Coelho, Angela Dispenzieri, et al.
Pageof 5